



LUND UNIVERSITY

Nordic MCL3 study: Y-90-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma

Kolstad, Arne; Laurell, Anna; Jerkeman, Mats; Gronbaek, Kirsten; Elonen, Erkki; Raty, Riikka; Pedersen, Lone Bredo; Loft, Annika; Bogsrud, Trond Velde; Kimby, Eva; Hansen, Per Boye; Fagerli, Unn-Merete; Nilsson-Ehle, Herman; Lauritzsen, Grete Fossum; Lehmann, Anne Kristine; Sundstrom, Christer; Karjalainen-Lindsberg, Marja-Liisa; Ralfkiaer, Elisabeth; Ehinger, Mats; Delabie, Jan; Bentzen, Hans; Schildt, Jukka; Kostova-Aherdan, Kamelia; Frederiksen, Henrik; Brown, Peter de Nully; Geisler, Christian H.

Published in:
Blood

DOI:
[10.1182/blood-2013-12-541953](https://doi.org/10.1182/blood-2013-12-541953)

2014

[Link to publication](#)

Citation for published version (APA):

Kolstad, A., Laurell, A., Jerkeman, M., Gronbaek, K., Elonen, E., Raty, R., Pedersen, L. B., Loft, A., Bogsrud, T. V., Kimby, E., Hansen, P. B., Fagerli, U.-M., Nilsson-Ehle, H., Lauritzsen, G. F., Lehmann, A. K., Sundstrom, C., Karjalainen-Lindsberg, M.-L., Ralfkiaer, E., Ehinger, M., ... Geisler, C. H. (2014). Nordic MCL3 study: Y-90-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. *Blood*, 123(19), 2953-2959. <https://doi.org/10.1182/blood-2013-12-541953>

Total number of authors:
26

General rights

Unless other specific re-use rights are stated the following general rights apply:
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Download date: 07. Dec. 2025

LUND UNIVERSITY

PO Box 117
221 00 Lund
+46 46-222 00 00

Nordic Mantle Cell Lymphoma-3 study: Zevalin-BEAM/C conditioning followed by autologous stem cell transplantation in first line therapy -

No benefit of Zevalin

Arne Kolstad¹, Anna Laurell², Mats Jerkeman³, Kirsten Grønbaek⁴, Erkki Elonen⁵, Riikka Rätty⁵, Lone Bredo Pedersen⁴, Annika Loft⁶, Trond Velde Bogsrud⁷, Eva Kimby⁸, Per Boye Hansen⁹, Unn-Merete Fagerli¹⁰, Herman Nilsson-Ehle¹¹, Grete Fossum Lauritzsen¹, Anne Kristine Lehmann¹², Christer Sundstrom¹³, Marja-Liisa Karjalainen-Lindsberg¹⁴, Elisabeth Ralfkiaer¹⁵, Mats Ehinger¹⁶, Jan Delabie¹⁷, Hans Bentzen¹⁸, Jukka Schildt¹⁹, Kamelia Kostova-Aherdan²⁰, Henrik Frederiksen²¹, Peter de Nully Brown⁴ and Christian H. Geisler⁴ on behalf of the Nordic Lymphoma Group

¹Oncology, Oslo University Hospital, Oslo, Norway; ²Oncology, Uppsala University Hospital, Uppsala, Sweden; ³Oncology, Skåne University Hospital, Lund, Sweden; ⁴Hematology, Copenhagen University Hospital, Copenhagen, Denmark; ⁵Hematology, Helsinki University Hospital, Helsinki, Finland; ⁶PET and Cyclotron Unit, Copenhagen University Hospital, Denmark; ⁷Nuclear Medicine, Oslo University Hospital, Oslo, Norway; ⁸Hematology, Karolinska University Hospital, Solna, Sweden; ⁹Hematology, Herlev University Hospital, Denmark; ¹⁰Oncology, St.

No benefit from Zevalin-BEAM/C in MCL

Olavs University Hospital, Norway; ¹¹Hematology, Sahlgrenska University Hospital, Sweden; ¹²Oncology, Haukeland University Hospital, Norway; ¹³Pathology, Uppsala University Hospital, Sweden; ¹⁴Pathology, Helsinki University Hospital, Helsinki, Finland; ¹⁵Clinical Pathology, Copenhagen University Hospital, Denmark; ¹⁶Clinical Pathology, Skåne University Hospital, Sweden; ¹⁷Pathology, Oslo University Hospital, Norway; ¹⁸Hematology, Aarhus University Hospital, Denmark; ¹⁹Nuclear Medicine, Helsinki University Hospital, Finland; ²⁰Nuclear Medicine, Uppsala University Hospital, Sweden; ²¹Hematology, Odense University Hospital, Denmark

Corresponding author: Arne Kolstad,

Department of Oncology, Oslo University Hospital, Norwegian Radium Hospital, PO box 4590, Nydalen, 0424 Oslo, Norway.

Tel: +47 22934000

Fax: +47 22935599

E-mail: arnek@ous-hf.no

Abstract

Purpose: Since in previous Nordic MCL2 study based on high-dose immunochemotherapy with stem cell support, the response duration was significantly shorter for patients not in CR before the transplant, the main objective of the present MCL3 study was to improve outcome for this patient cohort by adding radioimmunotherapy with ^{90}Y -Ibritumomab-Tiuxetan (Zevalin) to the high-dose regimen.

Materials and Methods: Newly diagnosed stage II-IV MCL patients < 66 years received rituximab(R)- maxi-CHOP alternating with R-high-dose Ara-C (6 cycles total), followed by high-dose BEAM or BEAC and autologous stem cell transplantation. Intensification with Zevalin (0.4 mCi/kg) was given to patients in CRu/PR one week prior to high-dose therapy. Follow-up included CT-scans and minimal residual disease (MRD) measurement. Patients who developed solely molecular relapse received 4 weekly doses of rituximab.

Results: 160 consecutive MCL patients were included from 2005-2009. Overall response rate pre-transplant was 97% (CR: 51%, CRu: 17%, PR: 29%). After a median follow-up of 4.4 years the 4-year overall survival (OS), event free survival (EFS), and progression-free survival (PFS) were 78, 62 and 71%, respectively, similar to the MCL2 trial. Zevalin did not improve response duration for patients in CRu/PR. Inferior PFS, EFS- and OS were predicted by PET-positivity pre-transplant and MRD post-transplant. Zevalin added no acute toxicity. However, a trend towards higher MDS/AML rate was observed among Zevalin recipients.

No benefit from Zevalin-BEAM/C in MCL

Discussion: Late intensification with Zevalin did not improve outcome of patients in only CRu/PR before transplant. A positive PET prior to transplant was an even better predictor for outcome than detection of MRD after transplant

INTRODUCTION

Mantle cell lymphoma (MCL) comprises 5-10% of non-Hodgkin`s lymphomas (NHL) and often has an aggressive clinical course. At diagnosis, the disease is typically in stage III-IV with universal lymphadenopathy and bone marrow involvement¹. Other extranodal sites like the gastrointestinal tract are often involved². In addition to a characteristic immunophenotype, the hallmark chromosomal translocation t(11:14) leading to aberrant expression of cyclin-D1 can be found in most cases³. The importance of an effective induction regimen containing both Ara-C and rituximab has gained support based on results from phase-II and III trials⁴⁻⁷. MCL is known to be highly radiosensitive and anti-CD20 targeted radioimmunotherapy (RIT) with ⁹⁰Y- Ibritumomab-Tiuxetan (Zevalin) or ¹³¹I-tositumomab (Bexxar) has been shown is effective and well tolerated⁸⁻¹⁰. Since myelosuppression is the major toxicity of these strategies, standard dose RIT plus myeloablative chemotherapy followed by stem cell rescue has been tested with promising results in MCL and other NHL^{8,11}.

The Nordic phase-II MCL2 study which included 160 patients showed a strong correlation between the response pre-transplant and long-term PFS and OS. Hence, in the present study (MCL3), responders who did not achieve a CR after induction immunochemotherapy were

No benefit from Zevalin-BEAM/C in MCL

offered late intensification with standard dose Zevalin (0.4 mCi/kg) prior to high-dose treatment with BEAM or BEAC (Z-BEAM/C). The main objective was to improve duration of response in this patient subset.

PATIENTS and METHODS

Patients, diagnostic work-up and follow-up

The Nordic Lymphoma Group has conducted three successive phase II trials since 1996, including the present MCL3 study which recruited 160 patients from 2005 to 2009. The eligibility criteria were identical: Previously untreated stage II-IV MCL patients <66 years. The diagnostic specimens should fulfill the WHO criteria for MCL³ regarding immunophenotype, cyclinD1 overexpression or t(11;14) by central pathology review. Patients underwent standard clinical and laboratory work-up including CT scans of chest and abdomen, bone marrow biopsy and aspirates for histology and flow cytometry. Blood and bone marrow aspirates were sent to a central laboratory (Leukemia Marker Laboratory, Department of Hematology, Rigshospitalet, Copenhagen, Denmark) for identification of disease- or patient-specific molecular markers. Mantle cell lymphoma international index (MIPI) score and MIPI-B (B: biologic) scores¹² were assessed at inclusion. The complete work-up was repeated after the fifth cycle of induction therapy and three months after the transplant. A PET/CT scan should be done after cycle 5 whenever feasible, especially for patients who had not achieved CR by regular CT scan, but should not influence treatment choice or response evaluation. PET scans were centrally reviewed in Sweden, Finland and Norway and in Denmark by experts at 4 large university

No benefit from Zevalin-BEAM/C in MCL

clinics. The scans were scored according to the Deauville¹³ criteria with a five-point scale, where scores of 4 or 5 were considered positive. Follow-up visits were done every 6 months for 5 years with clinical examination, CT-scans, and blood and bone marrow samples. After 5 years, patients in remission continued annual follow-up with clinical assessment and blood samples. The Nordic MCL3 protocol was approved by all relevant Medicines Agencies and Ethics Committees. Informed consent was obtained from all patients in accordance with the Declaration of Helsinki. The study was registered at ClinicalTrials.gov (NCT00514475).

Treatment

Induction therapy for the MCL2 and MCL3 trials consisted of a total of 6 cycles of alternating maxi-CHOP-rituximab and high-dose Ara-C-rituximab administered every third week with G-CSF support⁵. Patients responding after five cycles underwent stem cell mobilization and peripheral blood stem cell harvest after the sixth cycle (Ara-C-rituximab). For in-vivo purging an extra dose of rituximab was administered at day 9 in cycle 6. A minimum of 2×10^6 CD34+ cells/kg was required to proceed to high-dose therapy with stem cell support. Responders who only achieved CRu or PR after cycle 5 were offered late intensification with standard dose of Zevalin (⁹⁰Y-Ibritumomab-Tiuxetan 0.4 mCi/kg, max. 32 mCi) one week before start of high-dose chemotherapy. Rituximab 250 mg/m² was given both one week before and just prior to Zevalin. As described for MCL2⁵, BEAM or BEAC conditioning was then given followed by stem cell infusion. During follow-up, patients who converted to PCR positivity without signs of clinical relapse were offered preemptive treatment with rituximab 375 mg/m² weekly for 4 weeks.

No benefit from Zevalin-BEAM/C in MCL

Detection of minimal residual disease

As described elsewhere^{16,17} fresh samples of blood and bone marrow was shipped overnight from all centers to the central laboratory in Copenhagen. Briefly, DNA was extracted and used for PCR primer design and standard nested PCR amplification of patient specific clonally rearranged immunoglobulin heavy chain genes (IGHV) and/or Bcl-1/IGHV rearrangement (translocation 11;14). Blood and bone marrow analyses were then performed after the fifth cycle of induction treatment, 3 and 6 months after transplant and then every 6 months in order to detect minimal residual disease and molecular relapse. PCR-positive follow-up samples were sequenced in order to secure identity with the original IGHV sequence/t(11;14).

Response criteria, end points and statistics

Response, EFS, PFS, OS and response duration were assessed according to NCI criteria¹⁴.

Response duration was calculated for responding patients who completed the therapy, from the date of first documentation of response until the date of relapse or progression of lymphoma.

Survival analyses were performed according to the Kaplan-Meier method¹⁵ and differences between subgroups were analyzed by the log-rank test. Multivariate Cox regression analysis was performed to assess the effect of prognostic factors on outcome.

RESULTS

Between 2005 and 2009, 162 previously untreated patients 18-65 years of age were recruited.

The inclusion and exclusion criteria were the same as for the previously reported MCL2 trial⁵. At

No benefit from Zevalin-BEAM/C in MCL

central pathology review only one case was excluded as non-MCL lymphoma. Another patient was excluded due to a concomitant renal cell carcinoma, leaving 160 evaluable patients. The characteristics of the MCL3 and MCL2 patients are shown in table 1 and are highly similar, with a median age of 58 years and the majority in stage IV with bone marrow infiltration, and a typical distribution between MIPI risk groups and pattern of Ki67 expression (table 1).

Study-terminating events, event-free and overall survival

A consort diagram is given in Figure 1. With a median observation time of 4.4 years, study-terminating events have occurred in 67 patients (42%), in 48 (30%) due to lack of response, relapse or progression, in 6 (4%) due to harvest failure, in 3 (2%) due to toxicity and in 10 (6%) due to death from other causes than MCL during treatment or after. The 4-year EFS for the MCL3 cohort was 62%. Forty-one patients have died, 30 of lymphoma and 11 of other causes: One sudden death after induction cycle 1, three from transplant complications (BEAM/C: 2, Z-BEAM/C: 1), three from secondary MDS/AML and four from other causes during follow-up (one each of: suicide, accident, large bowel cancer, infection). The 4-year OS rate was 78%. Both the EFS and OS curves for MCL3 and MCL2 were superimposable (Figure 2).

Response and progression free survival

At the first response evaluation after 5 cycles of therapy, prior to transplant, 155 patients (97%) had responded to the induction treatment, similarly to 96% in the MCL2 cohort⁵. Eighty-two (51%) had achieved CR, 26 (16%) CRu and 47 (29%) PR. Of the 155 responders, 146 proceeded

No benefit from Zevalin-BEAM/C in MCL

to transplant, whereas 9 did not (6 harvest failure, 3 toxicity). After the transplant, the number of patients in CR had increased to 119 (82%), 13 (9%) remained in CRu, 6 (4%) in PR, 4 (3%) had progressed and 4 (3%) had died. A total of 52 patients have relapsed or progressed during induction or follow-up. The 4-year- PFS was 71%, identical to that of the MCL2 study (Figure 2). No relapses have so far occurred among 34 patients observed in remission beyond five years after transplant.

Impact of Zevalin

Compared to MCL2, there was no improvement in response duration for the CRu/PR cohort despite the fact that 96% of the patients (64 of 67 patients in CRu or PR) eligible for Zevalin according to protocol did actually receive it (Figure 1). Twenty-seven of the 67 patients (40%) in CRu/PR have later relapsed or progressed, compared to only 16 of the 79 patients (20%) in CR with a projected 4-year response duration of 58% and 81%, respectively ($P=0.001$, Figure 3). Regarding toxicity, we did not observe unexpected severe adverse events related to Z-BEAM/C treatment and engraftment in terms of recovery time of absolute neutrophil (ANC) or platelet counts, which did not differ significantly from those of regular BEAM/C (not shown). However, there was a slight trend of higher incidence of secondary MDS or AML among those who did receive Zevalin (4 of 65), including one treated with Zevalin outside protocol after failed stem cell harvest), compared to only one of the 82 transplanted without Zevalin ($P=0.17$).

No benefit from Zevalin-BEAM/C in MCL

PET-scan prior to transplant predicts outcome

PET/CT was performed in 125 patients after cycle 5 of the induction treatment and 18 patients (14%) were scored PET positive. As expected, patients who were in PR by regular CT were more often PET positive compared to patients in CRu (36% vs 8%). Only one patient in CR had a positive PET-scan. Thirteen of 18 PET-positive patients (72%) have progressed/relapsed, compared to 26 of 107 (23%) PET-negative patients ($p < 0.0001$). With a median observation time of 4.4 years the 4-year PFS of the PET positive cohort was 27%, significantly worse than the 78% of the PET negative group. This translated into inferior OS for patients who had a positive PET-scan before transplant (Figure 4).

Detection of minimal residual disease before and after transplant

Prior to the transplant 47 of 99 patients (47%) were MRD positive in blood and/or bone marrow, compared to only 18 of 107 (17%) patients tested after transplant. Of patients tested at both time-points, 26 of the MRD positive cases had converted to MRD-negative posttransplant, suggesting that high-dose therapy improved the quality of the remission. Patients who were MRD positive prior to transplant had a significantly shorter PFS than patients who were MRD negative (Figure 5). After the transplant, a positive MRD was shown to be an even stronger predictor of outcome: Among the 18 patients who were MRD positive post-transplant, 12 (67%) have relapsed, compared to only 16 out of 89 patients (18%) in the MRD

No benefit from Zevalin-BEAM/C in MCL

negative group ($P < 0.0001$). Interestingly, 10 of the 14 PET positive patients who had a PCR primer were also MRD positive before transplant and 8 of these patients have relapsed.

Prognostic factors

Similar to the MCL2 study population, MIPI and MIPI-B were strong predictors for outcome¹⁶. The 5-year survival of MIPI low and intermediate risk groups did not differ significantly (82 and 72%, respectively) while it was 50% for the MIPI high risk patients (not shown). Of MIPI-B variables (age, WHO, WBC, LDH, Ki-67) only WHO performance status was shown to be an independent prognostic factor for EFS and LDH for OS in a multivariate analyses (Table 2). In addition, blastoid type of MCL was significant for inferior EFS, PFS and OS. In patients with available MRD primer and PET-scan performed, MIPI-B, a positive PET pretransplant and detectable MRD post-transplant were independent variables for EFS, PFS and OS (Table 3). A positive pre-transplant PET proved to be a stronger predictor for OS (HR 13.79, 95% CI 4.07-46.8, $p < 0.0001$) than post-transplant MRD (HR 4.76, 95% CI 1.46-15.5, $p < 0.001$).

DISCUSSION

We have demonstrated that –despite the major improvement in the treatment of younger MCL patients reported for MCL2^{5,6}, patients who do not achieve a CR after induction treatment have a poorer outcome. In order to improve this, we here in the MCL3 study offered such patients late intensification with Z-BEAM/C. Compared to the excellent historic control of the Nordic MCL2 patients, we did not succeed in reaching this objective. We confirm that the optimal

No benefit from Zevalin-BEAM/C in MCL

remission achieved before the transplant, assessed with both PET-scans and minimal residual disease, is the most important factor for the outcome.

Because MCL is highly radiosensitive and expresses surface CD20, targeting radiation directly to the malignant cells with Zevalin is an attractive strategy. Continued exposure to radiation would prevent the tumor cells from DNA damage repair¹⁷. Wang and colleagues⁹ found a response rate of 31% and favorable safety profile in heavily pretreated MCL patients who received Zevalin as single agent. As frontline treatment, Zevalin consolidation after 4 cycles of R-CHOP improved response rates in the ECOG trial E1499¹⁰, and ¹³¹I-tositumomab (Bexxar) followed by CHOP chemotherapy led to a response rate of 86% with 67% CR¹⁸. Yttrium-90 is a pure β -emitting isotope with energy and path length theoretically yielding a higher cross-fire effect on macroscopic tumors than on single tumor cells. Based on this, we selected patients with residual disease visible on CT before transplant for Zevalin treatment (CRu and PR). Since the treatment was followed by stem cell rescue, Zevalin was not expected to increase hematological toxicity. Accordingly, Gopal et al¹⁹ treated 16 patients with relapsed MCL with high-dose Bexxar plus chemotherapy followed by autologous stem cell support, and found no unexpected grade III/IV toxicities, and 3-year PFS and OS of 61% and 93%, respectively. Standard dose Zevalin (0.4 mCi/kg) added to high-dose BEAM, similar to our strategy, was first evaluated in a phase II trial for patients with relapsed aggressive NHL⁸ and shown to be well tolerated with median time to WBC and platelet engraftment of 11 and 12 days, and median 2-year PFS and OS of 70% and 89%, respectively. A recent randomized study that compared high-dose BEAM with Z-BEAM in

No benefit from Zevalin-BEAM/C in MCL

43 patients with relapsed or refractory aggressive lymphoma¹¹ reported a trend towards a higher rate of mucositis and serious infections in the Z-BEAM arm but no difference in engraftment kinetics. There was a statistically significant benefit of Zevalin-BEAM over BEAM in regards to PFS (59% vs 30%) and OS (91% vs 62%) at two years. In contrast, the CRu/PR patients of our prospective study did not benefit from late intensification with standard dose Zevalin-BEAM/C, compared to the MCL2 patients. This was also the case in PR patients with a PET-positive mass, where crossfire might be expected to play a role.

Secondary MDS or AML is a well known complication of extensive exposure to chemotherapy,^{20,21} including high-dose therapy with autologous stem cell transplantation where a cumulative incidence of 5-10% has been reported²². There has been concern that Zevalin, especially in heavily pretreated patients, may predispose for MDS/AML. However, Czuczman et al²³ investigating the incidence of MDS or AML in 746 patients with non-Hodgkin's lymphoma treated with Zevalin across 5 studies, found 19 (2.5%) MDS/AML cases with a median follow-up of 4.4 years, a rate not higher than expected in a patient population heavily pretreated with cytotoxic agents. Our incidence of MDS/AML of 4 of 65 is 6% (3 patients who received Z-BEAM/C and one receiving Zevalin alone after failure to harvest stem cells), but with wide confidence interval (95% confidence interval: 0.2-12%). In contrast only one patient in MCL3 and one in MCL2 who received BEAM without Zevalin, developed MDS/AML. These figures are too low to draw any conclusions, but warrant further critical attention about the risk of MDS following RIT, especially when combined with high-dose chemotherapy.

No benefit from Zevalin-BEAM/C in MCL

There is not yet consensus on the use of FDG PET scan in MCL. In the most recent update of the International Working Group response criteria²⁴ sufficient evidence was not found to recommend PET for staging, response evaluation or post-therapy surveillance in this lymphoma subtype. Recent reports, however, suggest a relevance of PET in response assessment²⁵⁻²⁷. In our prospective study a positive PET scan pretransplant was associated with a median PFS of less than 3 years, significantly shorter than in the PET negative cohort. The PET positive PR group is of particular interest: According to the revised response criteria²⁸ in routinely FDG avid lymphoma including MCL, any PET negative residual mass is compatible with CR. Accordingly, the outcome of our PET negative patients did not differ irrespective being in PR, CR or CRu. In multivariate analysis a positive pre-transplant PET-scan proved to be more important than CT-scan and MIPI-B, and also to post-transplant MRD in predicting PFS, EFS and particularly OS. In retrospective studies^{26,27}, a positive post-treatment PET-scan also predicted early relapse. Our prospective PET based results strongly suggest a value of this modality in the evaluation of response in MCL.

Minimal residual disease monitoring has been shown in our previous Nordic MCL2 study to be of value to predict prognosis in MCL⁶. Furthermore, preemptive rituximab treatment of molecular relapse often converts patients to MRD negative and may delay clinical relapse²⁹. Pott and colleagues³⁰ first showed that molecular remission posttransplant in MCL was highly predictive for outcome, with a median PFS of 92 months in the MRD negative group compared

No benefit from Zevalin-BEAM/C in MCL

to 21 months in the MRD positive group ($p < 0.001$). MRD monitoring has since been performed in the European MCL Network trials and has contributed to a better understanding of quality of remission and risk of relapse³¹. In the MCL Younger study the rate of MRD negativity in the bone marrow rose from 50% to 75% after consolidation with high-dose therapy³². These results correspond well to our data from MCL3, where 56% of patients were MRD negative before the transplant compared to 86% after. In a multivariate analysis MRD post-transplant independently contributed to predict PFS, EFS and OS. Hence, our data are in line with results from the MCL Younger study, suggesting that the tumor reduction achieved by high-dose consolidation contributes to long-term disease-free survival in MCL.

In conclusion late intensification with Zevalin added to BEAM/C before the transplant did not improve duration of response for patients only in CRu or PR compared to a historic control group (MCL2) and a trend was noted that Zevalin might contribute to a higher rate of MDS or AML. In addition to standard clinical response assessment, a positive PET-scan prior to transplant and detection of MRD in bone marrow or blood before or after transplant predicted higher rates of relapse and shorter PFS. For patients with less than a complete response prior to transplant, intervention at that time point may be too late to change the course of disease. High-risk patients can be identified up front by the MIPI and MIPI-B scores, and new strategies are warranted to improve the induction treatment in such patients.

No benefit from Zevalin-BEAM/C in MCL

Acknowledgements

The authors thank the medical and nursing staff at all collaborating centers and especially all patients participating in this study.

REFERENCES

1. Tiemann M, Schrader C, Klapper W, et al: Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. *Br J Haematol* 131:29-38, 2005
2. Oinonen R, Franssila K, Teerenhovi L, et al: Mantle cell lymphoma: clinical features, treatment and prognosis of 94 patients. *Eur J Cancer* 34:329-36, 1998
3. Swerdlow SH, Berger F, Isaacson PI: Mantle cell lymphoma. In: World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of Haematopoietic and Lymphoid Tissues (eds by E.S. Jaffe, N.L. Harris, H. Stein and J.W. Vardiman), IARC Press, Lyon, France:168-170, 2001
4. Romaguera JE, Fayad L, Rodriguez MA, et al: High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. *J Clin Oncol* 23:7013-23, 2005
5. Geisler CH, Kolstad A, Laurell A, et al: Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. *Blood* 112:2687-93, 2008
6. Geisler CH, Kolstad A, Laurell A, et al: Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. *Br J Haematol* 158:355-62, 2012
7. van 't Veer MB, de Jong D, MacKenzie M, et al: High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. *Br J Haematol* 144:524-30, 2009
8. Krishnan A, Nademanee A, Fung HC, et al: Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. *J Clin Oncol* 26:90-5, 2008
9. Wang M, Oki Y, Pro B, et al: Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. *J Clin Oncol* 27:5213-8, 2009
10. Smith MR, Li H, Gordon L, et al: Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by

yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499. *J Clin Oncol* 30:3119-26, 2012

11. Shimoni A, Avivi I, Rowe JM, et al: A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. *Cancer* 118:4706-14, 2012

12. Hoster E, Dreyling M, Klapper W, et al: A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. *Blood* 111:558-65, 2008

13. Meignan M, Gallamini A, Meignan M, et al: Report on the First International Workshop on Interim-PET-Scan in Lymphoma. *Leuk Lymphoma* 50:1257-60, 2009

14. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. *J Clin Oncol* 17:1244, 1999

15. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. *J Am Statist Assoc* 53:457-481, 1958

16. Geisler CH, Kolstad A, Laurell A, et al: The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). *Blood* 115:1530-3, 2010

17. Press OW, Rasey J: Principles of radioimmunotherapy for hematologists and oncologists. *Semin Oncol* 27:62-73, 2000

18. Zelenetz AD, Noy A, Pandit-Taskar N, et al: Sequential radioimmunotherapy with tositumomab/iodine I131 tositumomab followed by CHOP for mantle cell lymphoma demonstrates RIT can induce molecular remissions. *J Clin Oncol* 24:436s:Abstract 7560, 2006

19. Gopal AK, Rajendran JG, Petersdorf SH, et al: High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. *Blood* 99:3158-62, 2002

20. Morrison VA, Rai KR, Peterson BL, et al: Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. *J Clin Oncol* 20:3878-84, 2002

21. Mauritzson N, Albin M, Rylander L, et al: Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001. *Leukemia* 16:2366-78, 2002

22. Armitage JO, Carbone PP, Connors JM, et al: Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. *J Clin Oncol* 21:897-906, 2003

23. Czuczman MS, Emmanouilides C, Darif M, et al: Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. *J Clin Oncol* 25:4285-92, 2007

24. Juweid ME, Stroobants S, Hoekstra OS, et al: Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. *J Clin Oncol* 25:571-8, 2007

25. Bodet-Milin C, Touzeau C, Leux C, et al: Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group. *Eur J Nucl Med Mol Imaging* 37:1633-42, 2010
26. Mato AR, Svoboda J, Feldman T, et al: Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD. *Cancer* 118:3565-70, 2012
27. Cohen JB, Hall NC, Ruppert AS, et al: Association of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma. *Bone Marrow Transplant* 48:1212-17, 2013
28. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. *J Clin Oncol* 25:579-86, 2007
29. Andersen NS, Pedersen LB, Laurell A, et al: Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. *J Clin Oncol* 27:4365-70, 2009
30. Pott C, Schrader C, Gesk S, et al: Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. *Blood* 107:2271-8, 2006
31. Pott C, Hoster E, Delfau-Larue MH, et al: Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. *Blood* 115:3215-23, 2010
32. Dreyling M, Kluin-Nelemans HC, Bea S, et al: Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network. *Leuk Lymphoma* 52:2226-36, 2011

Legends Figure 1

Consort diagram of patients flow

Legends Figure 2

Survival. Event-free (A), progressions-free (B) and overall survival (C) of patients in MCL2 and MCL3 based on intention-to-treat of all included patients.

Legends Figure 3

Response duration in MCL2 and MCL3 of patients in CR, CRu and PR prior to transplant including all patients who completed therapy.

Legends Figure 4

Progression-free (A) and overall survival (B) for patients according to results of PET-scan prior to transplant

Legends Figure 5

Progression-free survival of patients according to results of MRD analysis before (A) and after (B) transplant

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Table 1. Characteristics of patients in MCL3 compared to MCL2

Variable	Category	MCL3	MCL2	p value
Male sex		129 (80%)	113 (71%)	0.05
Median age (range)		58 (28-65)	56 (32-65)	
Stage IV		139 (88%)	136 (85%)	0.37
MIPI score	Low	77 (48%)	80 (51%)	0.75
	Intermediate	49 (31%)	41 (26%)	
	High	33 (21%)	37 (23%)	
Cytologic variant	Blastoid	28 (18%)	31 (19%)	0.36
	Common	128 (82%)	129 (81%)	
% Ki-67	0-9	11 (9%)	10 (8%)	0.94
	10-29	61 (49%)	60 (50%)	
	>29	53 (42%)	50 (42%)	

Table 2. Multivariate analysis of 142 patients with available Ki-67 value according to outcome

Variable	Score	Event-free survival			Progression-free survival			Survival		
		Hazard Ratio	95% CI	P value	Hazard Ratio	95% CI	P value	Hazard Ratio	95% CI	P value
Age	Value	0.99	0.96-1.03	0.776	0.99	0.96-1.03	0.804	1.01	0.96-1.06	0.670
WHO Perform	0-1/2-4	2.84	1.28-6.29	0.010	2.13	0.95-4.77	0.065	1.68	0.66-4.29	0.275
Sex	M/F	1.19	0.64-2.24	0.582	1.12	0.63-2.26	0.575	0.82	0.36-1.89	0.647
Stage	II/III-IV	0.57	0.17-1.91	0.363	0.64	0.19-2.13	0.464	0.54	0.12-2.46	0.424
Cytology	Common /Blastoid	1.78	0.96-3.30	0.067	2.11	1.15-3.88	0.015	3.43	1.74-6.77	<0.001
KI-67	0-30/30+	1.17	0.61-2.23	0.638	1.22	0.63-2.35	0.558	1.44	0.66-3.13	0.361
LDH	Normal/elevated	1.36	0.76-2.41	0.298	1.42	0.80-2.53	0.228	2.34	1.17-4.69	0.017
Wbc	0-11/11+	1.43	0.81-2.54	0.218	1.51	0.85-2.67	0.161	1.62	0.83-3.18	0.157

Table 3. Multivariate analysis of 82 patients with available MRD and PET data and who completed transplant

		Event-free survival			Progression-free survival			Survival		
Variable	Score	Hazard Ratio	95% CI	P value	Hazard Ratio	95% CI	P value	Hazard Ratio	95% CI	P value
MIPI-B	Value	2.15	1.27-3.65	0.004	2.29	1.33-3.95	0.003	3.52	1.69-7.31	0.001
PET response pre-Tx	Pos/neg	6.00	2.37-15.19	<0.001	6.82	2.63-17.70	<.001	13.79	4.07-46.8	<.0001
CT response pre-Tx	CR/PR	1.99	0.81-4.92	0.134	2.20	0.87-5.61	0.097	3.66	0.89-15.1	0.073
MRD post-Tx	Pos/neg	4.58	1.92-10.89	0.001	4.98	2.07-12.01	<0.001	4.76	1.46-15.5	0.001